Palatin Technologies is expected to report consensus revenue of approximately $0.83 million and an EPS loss of $1.20 for the quarter ending June 30, 2026, with shares trading at $9.92 against a bullish $53.50 analyst target. Investors are primarily focused on the clinical development timeline for PL9643, specifically the anticipated New Drug Application (NDA) filing for the treatment of dry eye disease following breakthrough Phase 3 results.
Management commentary will also be scrutinized for updates on the MC4R-based obesity pipeline, including the once-weekly peptide agonist scheduled for IND submission in late 2026. Additionally, analysts are watching for signs of increased collaboration revenue and disciplined cash management as the company advances multiple melanocortin receptor-based programs.